These Functional Mushrooms Could Help Improve Your Mental Well-Being

The functional mushroom story is going mainstream. Not only can they help activate cell immunity in humans, as noted by The New Daily, mushrooms are thought to help with better sleep, energy, stress reduction, memory, and relaxation. Reportedly, mushrooms such as Reishi can help with sleep, anxiety, and depression. Chaga can help with inflammation for example. Turkey tail can help support the immune system, and assist with some cancer prevention.

In addition, according to The New York Times, “Lion’s mane, which has the look of a shaggy, faux-fur ottoman, was found in a 2016 study published by the Chinese Journal of Integrative Medicine to promote peripheral nerve regeneration in rats. For humans, the mushroom is typically used with the goal of enhancing concentration, memory and mental clarity. Nootropics “substances alleged to increase mental performance” are the next big thing. “Lion’s Mane” is a true nootropic because it permanently enhances cognition by improving the brain’s ability to alter itself structurally. Extract is alleged to improve improve the body’s ability to cover nerve tissues with myelin, which is a crucial factor in nerve growth. If true, this property could heal nerve damage and increase a person’s ability to learn. This means that Lion’s Mane consumption could lead to increased quality of life and economic productivity.

From here, the functional mushroom story is only likely to get stronger.

That’s good news for companies like Arev NanoTec Brands Inc. (CSE: AREV)(OTC: AREVF)

Arev NanoTec Brands just announced that it has completed the first stage of its Joint Venture agreement with Absolem Mushroom Extraction Inc. (a subsidiary of Absolem Health Inc.) as announced July 17, 2020, where Absolem selected AREV Brands to develop an exclusive extraction method for functional and medicinal mushrooms.

Absolem has paid CAD $20,000 as its cash portion for participation in the Joint Venture and issued 2,133,334 shares of Absolem Health Inc. to AREV Brands. AREV Brands has utilized the cash payment acquire certain extraction equipment that will be utilized to conduct research for the benefit of Absolem. Financially, AREV Brands owns 50% of the Joint Venture and holds a 6.6% equity interest in Absolem Health Inc. and accordingly will earn participatory revenues from the sale of extracts utilizing its equipment and SOP’s.

The Company has taken delivery of the pharmaceutical grade nanotechnology equipment and integrated it into its proprietary extraction systems. As the Company’s work has identified green solvents suitable for extraction of functional and medicinal fungi and commenced trials on optimizing extraction of phyto-compounds found in lion’s mane. Lions mane was selected as the initial mushroom to work with due to its legal status and unique functional properties for mental health, particularly dementia.

AREV’s extraction system and proprietary methods enable the extraction of a variety of specific natural active substances, which are naturally present in certain functional and medicinal mushrooms. It is these natural substances that are reputed to have fostered and created some of the beneficial claims, when certain types of mushroom species are ingested by humans as noted in many peer reviewed papers.

In the second phase of this Joint Venture, AREV Brands is focused on the beneficial features that are attributed to Hericium erinaceus, more commonly known as the “lion’s mane” mushroom. “This mushroom has a long history of use in traditional Chinese medicines, and it has recently been examined in formal Western medicinal studies with the conclusion that lion’s mane appears to be a “good candidate to regress recognition memory decline during aging... and could be a new therapeutic strategy for preventing or treating neurodegenerative dis- eases such as dementia and Alzheimer’s.” “Hericium erinaceus Improves Recognition Memory and Induces Hippocampal and Cerebellar Neurogenesis in Frail Mice during Aging.”

Both Absolem and AREV Brands are aware of the numerous additional naturally occurring wild and/or cultivated mush- rooms in existence, and we are currently expanding our focus accordingly.

The technology that is being created and utilized for this extraction is a result of certain permutations and combinations available within AREV Brands extraction facility. Each “refinement” procedure is being specifically designed for the extraction of the natural substance that is to be ultimately used as an active ingredient for an intended analgesic or possible solution to the particular health condition that is under review.

Plants and fungi might be viewed as natural “factories” which produce a broad variety of diverse compounds. Reported results of both human and animal use of these products have been recorded throughout history. Some of the information is in historic testimonial form and some is in presented in Western scientific formats. Relief of specific ailments provided from natural substances have been recorded ranging from temporary to permanent. Evidence of relief has been observed to occur throughout a variety of conditions of painful discomfort, including some amount of relief provided for anti-inflammatory situations, immune support, anti-biotic, oxidant, anxiety, nausea, depression and PTSD.

AREV Brands has begun to extract the ingredient(s) known to have been involved in the relief, perhaps only temporary, of symptoms currently experienced by a significant portion of the human and animal world.

Some Observations on Process Scale Extraction

The isolation and extraction of the substance(s) that produce positive results in a living being is an age old process. Ex- tractions are achieved via, fermentation, straining, filtration, centrifugal force, gravity, ultrasound, ethanol usage, water usage and numerous combinations of these and other activities.

Plants and fungi are natural chemical factories that produce diverse natural compounds: anti-inflammatory, immune sup- port, anti-viral, antibiotic, anti-cancer, analgesics, antioxidants, anxiety reduction, treatment for depression, and preservation of memory.

Process scale extraction allows multi-kilogram quantities of functional oils and fractionated materials from plants and fungi to be produced. All intellectual property generated through the extraction methods research, which relate to mush- room extraction methods will vest in Absolem and all other intellectual property shall vest in AREV Brands. This will include any scientific information related to organic chemistry extraction technologies.

Mr. Withrow has successfully established a cultivation lab and culture facility for growing Cordyceps in Ho Chi Minh City, Vietnam. His former company has four (4) NPN’s for Cordyceps registered with Health Canada. Mr. Withrow commented that “Completion of Phase 1 gives AREV Brands a stake in the exciting new functional and medicinal mushroom sectors via our holdings in Absolem.” He went on to say, “We now are on the way to being able to deliver a proprietary extraction method to the Absolem Extraction JV as planned.”

Other companies using mushrooms include:

Core One Labs Inc. (CSE:COOL)(OTC:CLABF), which just announced its wholly-owned subsidiary Vocan Biotechnologies Inc. has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant production of psilocybin. The process that engineers bacteria incorporating optimized biosynthetic genes from the Psilocybe cubensis mushroom, will enable the bacteria to act as a biological factory and synthesize psilocybin that is cost effective using simple building blocks.

MindMed (NEO:MMED)(OTC:MMEDF), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. In his most recent position, Mr. Barrow served as Director of Drug Development & Discovery at the Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs in psychedelics. At Usona, Mr. Barrow was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining Breakthrough Therapy Designation for the program at FDA.

Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), is excited to announce it has acquired the Orbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary instrument for its continued research and development of Psilocybe mushroom related projects at Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory. Implementation of the Orbitrap, a state-of-the-art high resolution mass spectrometry instrument, will continue the accelerated trajectory of Numinus Bioscience’s research strategy to optimize cultivation, harvest, and extraction of Psilocybe mushrooms. This follows Numinus’ successful completion of the first legal extraction in Canada by a public company for research and development purposes in December.

COMPASS Pathways Inc. (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States. The Centre of Excellence will model the “clinic of the future”, showcasing the best thinking in science, therapy, technology, and design. Working as a research facility and innovation lab, it will generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience. The first wave of research will focus on COMPASS’s investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Arev NanoTec Brands Inc. by a third party. We own ZERO shares of Arev NanoTec Brands Inc. Please click here for full disclaimer.

Contact Information:
[email protected]